Abstract

IntroductionLaparoscopic cystectomy provides more favourable outcomes as regards the recurrence and subsequent clinical pregnancy rates. It is associated with significant reduction in the ovarian reserve due to the inevitable removal of unaffected ovarian tissue. The aim of our study was to evaluate the efficiency of Surgicel in preventing recurrence of endometriomas after their laparoscopic conservative management (cystectomy or drainage).Material and methodsA randomized controlled trial included two hundred women (candidate for conservative laparoscopic management of ovarian endometriomas). They were randomized into four groups; group D in which patients underwent laparoscopic drainage of the endometrioma, group C in which patients underwent laparoscopic cystectomy of the endometrioma, group DS in which patients underwent laparoscopic drainage followed by insertion of Surgicel inside the cyst cavity & group CS in which patients underwent laparoscopic cystectomy of the endometrioma followed by insertion of Surgicel inside the remaining ovarian tissues. All patients were followed up for 2 years & the primary outcome was the recurrence of endometriomas in the ipsilateral ovary & the postoperative ovarian reserve was reassessed as a secondary outcome.ResultsThe Surgicel-treated groups had significantly lower hazard of recurrence compared to untreated groups (p = 0.004). Group CS had significantly lower hazard of recurrence compared to Group D & C (p = 0.014, 0.046 respectively). Group DS had significantly lower hazard of recurrence compared to Group D (p = 0.039) but it not significantly different from Group C (p = 0.112). Group DS had the lowest drop of AMH and was significantly lower than the other three groups.ConclusionSurgicel reduces effectively the recurrence risk of endometriomas and its use during laparoscopic drainage is an effective alternative for traditional laparoscopic cystectomy with minimal affection of the patient ovarian reserve.Trial registrationName of the registry: clinicaltrials.gov. Trial registration number NCT02947724. Date of registration October 28, 2016.

Highlights

  • Laparoscopic cystectomy provides more favourable outcomes as regards the recurrence and subsequent clinical pregnancy rates

  • Surgicel reduces effectively the recurrence risk of endometriomas and its use during laparoscopic drainage is an effective alternative for traditional laparoscopic cystectomy with minimal affection of the patient ovarian reserve

  • Participants were randomized into 4 groups; group D in which patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall, group C in which patients underwent laparoscopic excision of the endometrioma cyst wall, group Drainage & Surgicel (DS) in which patients underwent laparoscopic fenestration of the endometrioma cyst wall followed by insertion of 4–8 pieces of Surgicel inside the cyst cavity, group Cystectomy & Surgicel (CS) in which patients underwent laparoscopic excision of the endometrioma cyst wall followed by insertion of 4–8 pieces of Surgicel inside the remaining ovarian tissues

Read more

Summary

Introduction

Laparoscopic cystectomy provides more favourable outcomes as regards the recurrence and subsequent clinical pregnancy rates. It is associated with significant reduction in the ovarian reserve due to the inevitable removal of unaffected ovarian tissue. Endometriomas are ectopic endometrium that grows within the ovarian tissue forming cystic structures filled with dark altered blood. They are detected in 17– 44% of endometriosis cases [4]. Based on Cochrane systematic review, laparoscopic cystectomy provides more favourable outcomes as regards the recurrence of endometriomas & subsequent clinical pregnancy rate when compared with drainage & ablation [5]. Recurrence may be due to one or more of the following; de novo lesion, the regrowth of residual cells not removed during surgery or the growth of microscopic lesions unidentified at surgery [9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call